글로벌 골육종 약물 시장 – 2030년까지의 산업 동향 및 예측

골육종 약물 시장 분석 및 규모

대사 장애와 만성 신장 질환 (CKD) 의 증가로 인해 시장 성장이 증가할 것으로 예상됩니다 . 50세 이상의 대부분의 사람들은 골다공증을 앓을 것으로 예상되지만 일부는 뼈 질환이 발병할 위험이 있습니다. 골육종은 가장 흔한 유형의 암이며 일반적으로 어린이와 젊은 성인에게 발생합니다. 골육종과 같은 희귀 암에 대한 새로운 치료법에 대한 필요성이 빠르게 증가함에 따라 향후 몇 년 동안 시장 성장에 대한 잠재적 기회가 제공됩니다.                                

Data Bridge Market Research는 2022년에 1,200.00백만 달러였던 골육종 약물 시장이 2030년까지 1,840.00백만 달러로 급증할 것이며 예측 기간 동안 5.50%의 CAGR을 경험할 것으로 분석했습니다. 이는 시장 가치를 나타냅니다. "경구"는 골육종 치료를 위한 경구 약물에 대한 수요가 증가함에 따라 골육종 약물 시장의 투여 경로 부문을 지배합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

골육종 약물 시장 범위 및 세분화

시장 정의

글로벌 골육종 약물 시장은 구체적으로 골육종 치료를 위해 개발 및 판매되는 약물 및 치료법과 관련된 사업 활동 및 거래를 말합니다. 골육종은 주로 어린이와 젊은 성인에게 영향을 미치는 희귀한 형태의 뼈암입니다. 이 시장에는 골육종의 진단, 치료 및 치유를 위한 약물 및 치료법의 연구, 개발, 생산, 마케팅 및 판매가 포함됩니다.            

골육종 약물 시장 동향

운전자

• 여러 시장 참여자들의 약물 승인 증가

점점 더 많은 약물 승인이 시장 성장을 주도하고 있습니다. 예를 들어, 2010년에 FDA는 골절 위험이 높은 폐경 후 여성을 치료하기 위해 데노수맙이라는 단일 클론 항체를 승인했습니다. 또한 테리파라티드는 부갑상선 호르몬의 합성 형태이며 FDA에서 승인한 유일한 단백 동화 약물입니다. 인산 결합제와 투석도 고인산혈증 치료에 널리 사용됩니다. 이는 시장 성장을 촉진할 것입니다.

• 연구 및 개발 능력

특히 선진국과 개발도상국에서 치료 약물과 관련된 연구 개발 능력에 대한 지출이 증가하면서 수익성 있는 시장 성장 기회가 더욱 창출될 것입니다. 골육종 치료법을 개발하기 위해 수행되는 연구 개발 능력도 시장 성장률을 높이고 있습니다.

• 의료 시설에 대한 투자 증가

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Increased demand for chemotherapy

Increasing demand for chemotherapy is driving the growth of the market. For instance, Merck KGaA, a biopharmaceutical company in Darmstadt, Germany, in the United States and EMD Serono and Pfizer Inc. in Canada announced that the US Food and Drug Administration has approved the Supplemental Biologics License Application (sBLA) for BAVENCIO (avelumab). ) in April 2020 for the treatment of locally advanced or metastatic urothelial carcinoma (UC). Therefore, this factor contributes to the growth of the market.

• Increasing strategic alliances among market players

Major market players are focusing on inorganic growth strategies that are expected to drive market growth during the forecast period of 2023-2030. For instance, Amgen, one of the leading biotechnology companies in the world, is primarily focused on the clinical development and commercialization of MP0310, entering into a strategic collaboration with Molecular Partners in December 2018. MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP in tumor stromal cells and stimulating T cells with 4-1BB. Therefore, this factor accelerates the growth of the market.

Restraints/ Challenges

• Risk of side-effects

Many side effects associated with osteosarcoma drug may limit the growth of the global osteosarcoma drug market during the forecast period. Side effects such as dyspepsia, headache and to some extent myalgia, flushing, lower back pain and rhinitis have been reported with osteosarcoma medication. Therefore, these effects hinder the growth of the market.

• Lack of knowledge and awareness about osteosarcoma

Lack of expertise and knowledge about bone cancer in some low- and middle-income countries, such as Kenya and India, hinders market growth. Osteosarcoma is also not widely reported in these countries. Therefore, the availability of treatment is also lower. Therefore, this factor hinders the growth of the market.

This osteosarcoma drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteosarcoma drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2021, the Centers for Devices and Radiological Health of the FDA granted ZetaMet's breakthrough device for the treatment of metastatic bone cancers and osteological interventions.
•  In October 2020, Johnson and Johnson completed the acquisition of Momenta Pharmaceuticals Inc. acquisition to provide additional potential in various diseases, including infectious diseases and vaccines, neuroscience, oncology and pulmonary hypertension.

Global Osteosarcoma Drug Market Scope

The osteosarcoma drug market is segmented on the basis of types, treatment, mechanism of action, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Central Tumor
• Surface Tumor

Treatment

• Surgery
• Medication

Mechanism of Action

• Topo Isomerase Inhibitor
• RNA Synthesis Inhibitor
• Dihydrofolic Acid Reductase Inhibitor
• Monoclonal Antibody
• Others

Drugs

• Doxorubicin
• Methotrexate
• Dactinomycin
• Denosumab
• Cyclophosphamide
• Others

Route of Administration

• Oral
• Parenteral

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Osteosarcoma Drug Market Regional Analysis/Insights

The osteosarcoma drug market is analysed and market size insights and trends are provided by country types, treatment, mechanism of action, drugs, route of administration, end users and distribution channel as referenced above.

The countries covered in the osteosarcoma drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market because the presence of major key manufacturers of the product is high and growing research and development activities. The rise in the occurrence of bone cancer will boost the growth of the osteosarcoma drug market in the region during the forecast period 2023-2030.   

Asia-Pacific has been witnessing positive growth for osteosarcoma drug market throughout the forecasted period because of the increased new research and developments on osteosarcoma drug. Also, the incidence of well settled healthcare infrastructure is also increasing the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The osteosarcoma drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for osteosarcoma drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the osteosarcoma drug market. The data is available for historic period 2021-2030.

Competitive Landscape and Osteosarcoma Drug Market Share Analysis

The osteosarcoma drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteosarcoma drug market.

Some of the major players operating in the osteosarcoma drug market are:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland.)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Bellicum Phamaceuticals, Inc (U.S.)
• Incyte (U.S.)
• Nektar Therapeutics (U.S.)
•  Iovance Biotherapeutics (U.S.)
• Aurora biopharma (U.S.)
• BioAtla (U.S.)
• Acrotech Biopharma, Inc. (U.S.)
• Eleison Pharmaceuticals (U.S.)

SKU-50505